Clinical Trial: NCT02520791
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-11-12 |
Study Overview
Brief Summary
This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
Official Title
Conditions
Intervention / Treatment
- Biological: Anti-ICOS Monoclonal Antibody MEDI-570
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
Other Study ID Numbers
- NCI-2015-01271
- NCI-2015-01271
- PJC-021
- 9930
- 9930
- UM1CA186644
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-11-12 |
Study Overview
Brief Summary
This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
Official Title
Conditions
Intervention / Treatment
- Biological: Anti-ICOS Monoclonal Antibody MEDI-570
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
Other Study ID Numbers
- NCI-2015-01271
- NCI-2015-01271
- PJC-021
- 9930
- 9930
- UM1CA186644